Efficacy & Safety of Dry Powder Ivy Extract (Syrup Prospan) Versus NAC Among COPD Patients - Trial NCT06377410

Timeline & Enrollment

Primary Outcome

To assess cough symptoms and its impact on daily activities using Cough and Sputum Assessment Questionnaire (CASA-Q); scores for each domain range from 0 to 100, with higher scores indicating fewer/less severe symptoms and less impact.

Summary

As the third global leading cause of death, Chronic Obstructive Pulmonary Disease (COPD)
 affects more than 300 million people worldwide. These patients suffer from 0.5-3.5
 exacerbations per year on average. Each exacerbations dampened their health status as well as
 quality of life, not to mention a great burden to our healthcare system. Those partially
 treated or prolonged exacerbations would subsequently lead to unfavorable disease
 progression. Hence a holistic approach in managing each exacerbations is very crucial.
 
 Mucus hypersecretion in COPD patients plays a pivotal role in acute exacerbations and
 associated with unfavorable outcomes. These exacerbations comes with sputum increment as much
 as its purulence. Mucolytics are believed to to ease patient to expectorate and benefits them
 from tip into an exacerbations or even the consequent hospitalisation.
 
 Mucolytics work by reducing sputum viscosity hence improved its expectoration.
 N-acetylcysteine (NAC) is a mucolytic with antioxidant and anti-inflammatory properties,
 commonly used in practice among COPD patients. Meanwhile, Syrup Prospan is ivy leaf
 preparations, obtained as extracts from leaves of the plant Hedera helix L. It is widely used
 over-the-counter cough remedy containing saponins which are believed to have expectorant
 properties. Studies show evidence of antispasmodic, bonchodilating, anti-inflammatory and
 antitussive properties and its usage is authorised by the European Medicines Agency .

ICD-10 Classifications